Brain Advance Access originally published online on April 2, 2007
Brain 2007 130(5):1224-1234; doi:10.1093/brain/awm047
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis
1Department of Neurology, Tohoku University School of Medicine, Sendai, 2Department of Pathology and the Resource Branch for Brain Research CBBR, Brain Research Institute, Niigata University, Niigata and 3Department of Neurology, National Nishitaga Hospital, Sendai, Japan
Correspondence to: Dr Tatsuro Misu, MD, Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryomachi, Aobaku, Sendai 980-8574, Japan E-mail: misu{at}em.neurol.med.tohoku.ac.jp
 |
Summary |
|---|
 Top Summary IntroductionMaterial and methodsResultsDiscussionConclusionsReferences |
|---|
Neuromyelitis optica (NMO) is an inflammatory and necrotizing disease clinically characterized by selective involvement of the optic nerves and spinal cord. There has been a long controversy as to whether NMO is a variant of multiple sclerosis (MS) or a distinct disease. Recently, an NMO-specific antibody (NMO-IgG) was found in the sera from patients with NMO, and its target antigen was identified as aquaporin 4 (AQP4) water channel protein, mainly expressed in astroglial foot processes. However, the pathogenetic role of the AQP4 in NMO remains unknown. We did an immunohistopathological study on the distribution of AQP4, glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), activated complement C9neo and immunoglobulins in the spinal cord lesions and medulla oblongata of NMO (n = 12), MS (n = 6), brain and spinal infarction (n = 7) and normal control (n = 8). The most striking finding was that AQP4 immunoreactivity was lost in 60 out of a total of 67 acute and chronic NMO lesions (90%), but not in MS plaques. The extensive loss of AQP4 accompanied by decreased GFAP staining was evident, especially in the active perivascular lesions, where immunoglobulins and activated complements were deposited. Interestingly, in those NMO lesions, MBP-stained myelinated fibres were relatively preserved despite the loss of AQP4 and GFAP staining. The areas surrounding the lesions in NMO had enhanced expression of AQP4 and GFAP, which reflected reactive gliosis. In contrast, AQP4 immunoreactivity was well preserved and rather strongly stained in the demyelinating MS plaques, and infarcts were also stained for AQP4 from the very acute phase of necrosis to the chronic stage of astrogliosis. In normal controls, AQP4 was diffusely expressed in the entire tissue sections, but the staining in the spinal cord was stronger in the central grey matter than in the white matter. The present study demonstrated that the immunoreactivities of AQP4 and GFAP were consistently lost from the early stage of the lesions in NMO, notably in the perivascular regions with complement and immunoglobulin deposition. These features in NMO were distinct from those of MS and infarction as well as normal controls, and suggest that astrocytic impairment associated with the loss of AQP4 and humoral immunity may be important in the pathogenesis of NMO lesions.
Key Words: neuromyelitis optica; multiple sclerosis; aquaporin 4; astrocyte; necrosis
Abbreviations: GFAP, glial fibrillary acidic protein; AQP4, aquaporin 4; BBB, blood–brain barrier; LCA, leucocyte antigen; MBP, myelin basic protein; PLP, proteolipid protein; VEGF, vascular endothelial growth factor
Received November 10, 2006. Revised February 12, 2007. Accepted February 13, 2007.
|
Introduction |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionConclusionsReferences |
|---|
Neuromyelitis optica (NMO) is an idiopathic inflammatory, necrotizing disease characterized by selective involvement of the optic nerves and spinal cord (Cloys and Netsky, 1970
; Kuroiwa, 1985). Both monophasic and relapsing NMO have been known since the original description (Devic, 1894, Gault, 1895). Relapsing NMO has been called optic-spinal multiple sclerosis (OSMS) in Japan and other Asian countries (Kuroiwa, 1985; Misu et al., 2002). It has long been controversial whether NMO or Devic's disease is a variant of MS or a distinct disease. Recently, a number of distinctive clinical and laboratory features of relapsing NMO and OSMS differing from classical MS have been identified such as female-predominance, low frequencies of oligoclonal IgG band, longitudinally extensive (>3 vertebral segments) spinal cord lesions, polymorphonuclear cell-dominant pleocytosis, and poor clinical prognosis with blindness, tetraparesis and respiratory failure (Mandler et al., 1993; Wingerchuk et al., 1999; Misu et al., 2002; Kira, 2003). Neuropathological studies in NMO showed that tissue necrosis often associated with cavity formation and grey matter involvement was evident in addition to demyelination (Cloys and Netsky, 1970; Kuroiwa, 1985). Moreover, humoral immunity such as the perivascular deposition of immunoglobulin and complement, and the infiltration of neutrophils or eosinophils, were the dominant immunopathological features in the lesions of NMO (Mandler et al., 1993; Lucchinetti et al., 2002). In Japanese OSMS, it was reported that there were necrotic lesions with a loss of glial fibrillary acidic protein (GFAP) staining in the spinal cord lesions, but the mechanism of the astroglial defect has remained unknown (Itoyama et al., 1985).
Recently, a disease-specific autoantibody, NMO-IgG, was found in the sera from patients with Caucasian NMO and Japanese OSMS patients (Lennon et al., 2004). Subsequently, it was found that NMO-IgG bound selectively to aquaporin 4 (AQP4) water channel (Lennon et al., 2005), which is densely expressed in astrocytic foot processes at the blood–brain barrier (BBB) (Jung et al., 1994). Very recently, we reported a case of typical NMO which showed a loss of AQP4 immunostaining in the spinal cord lesions, especially in active perivascular lesions (Misu et al., 2006). Such a loss of AQP4 has not been found in demyelinating lesions of MS. Therefore, in the present study, we performed immunohistochemical analyses of AQP4 in more NMO cases to clarify whether the loss of AQP4 immunostaining in lesions commonly occurs in NMO lesions and is a distinctive pathological feature of NMO from MS and brain and spinal cord infarction.
|
Material and methods |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionConclusionsReferences |
|---|
Autopsied cases of NMO, MS and other neurological disorders
In the present study, we analysed 12 cases of NMO and 6 cases of MS. The clinical findings of the patients are summarized in Table 1. The median age was 52.5 (range 19–80) years in NMO (8 females and 4 males) and 46 (range 22–67) years in MS (3 females and 3 males). Disease durations ranged from 0.3 to 28 years in NMO (median, 3 years) and from 3 to 21 years in MS (median, 9.75 years). The clinical course of NMO was relapsing in 10 patients and monophasic in 2 patients. The diagnosis of NMO was made only by clinical manifestations (Wingerchuk et al., 1999
). The diagnosis of MS was made according to the Poser criteria (Poser et al., 1983).
|
In addition, as neurological and non-neurological controls, we studied 10 lesions of infarction including cerebral infarction in acute phase (n = 3) (two basal ganglia lesions and one subcortical lesion), cerebral infarction in chronic phase (n = 5) (one brainstem lesion, one occipital artery occlusion, two basal ganglia lesions and one subcortical lesion), two chronic spinal cord lesions of Foix–Alajouanine syndrome (n = 2), an angiodysgenetic necrotizing myelopathy and eight spinal cords of non-neurological and non-inflammatory diseases (n = 8).
Neuropathological techniques and immunohistochemistry
The spinal cords and brains of the cases and the optic nerve of a single case of NMO (NMO12) were processed for paraffin-embedded to routine procedures. Tissue slices of 5–6 µm thickness were cut and mounted serially on numbered slides so that the distribution of molecules such as AQP4, GFAP and myelin components were compared in adjacent serial sections. We stained all sections with haematoxylin and eosin (HE), Klüver–Barrera (KB) and Bodian staining.
We used the immunostaining system of avidin–biotinylated enzyme complex (ABC) (Vectastain, Vector, CA) or EnVision (DAKO, Carpinteria, CA). Briefly, at first the paraffin sections on slides were immersed in xylene for 5 min three times, and then they were immersed in 100% ethanol, 95% ethanol and then 90% ethanol for 5 min each. After washing with distilled water, we washed the slides three times with phosphate buffered saline (PBS). Non-specific binding was blocked with 10% goat serum for 15 min at room temperature, and the slides were covered with the primary antibodies listed in Table 2 and incubated for 1–48 h at the appropriate temperature. The primary antibody was omitted in the control study. Then, the slides were washed with PBS and incubated with PBS containing 30% methanol and 1 ml of H2O2 (30%) for 20 min followed by washing three times with PBS. Secondary antibodies were applied and incubated for 45 min to 1 h at room temperature according to the manufacturer's protocols. For staining, we used diaminobenzidine hydrochloride (DAB) (brown) for the horseradish peroxidase (HRP) system, and fuchsin (DAKO, Carpinteria, CA) (red) or Vector blue (Vector, CA) (blue) for the alkaline phosphatase (AP) system. Selected sections were counterstained with a filtered solution of haematoxylin (blue), methyl green (Vector) (green) or fast nuclear red (Vector) (red).
|
For double staining, we combined two enzyme systems, HRP and AP. For example, in the double staining of MBP and C9neo, we first applied mouse anti-human C9neo antibody and then incubated with HRP-conjugated anti-mouse IgG and stained by DAB according to the single staining procedure. After washing three times with PBS, we further applied rabbit anti-human MBP antibody and then incubated with AP-conjugated anti-rabbit IgG and stained by Vector blue. Counterstaining was done by methyl green or nuclear fast red, where applicable. The slides were mounted with VectaMount (Vector).
Lesion staging
We classified the lesions of NMO and MS into the following four stages (1–4):
(1) Acute inflammatory lesions, (2) actively demyelinating lesions, (3) chronic active lesions and (4) chronic inactive lesions.
‘Actively demyelinating’, ‘chronic active’ and ‘chronic inactive’ lesions were based on the histological staging criteria for MS lesions (Lassmann et al., 1998; Trapp et al., 1998), and we added ‘acute inflammatory’ lesions as the most acute phase of the disease, referring to the Vienna consensus (Lassmann et al., 1998). Acute inflammatory lesions are infiltrated with numerous perivascular mononuclear and/or polymorphonuclear cells with relatively small numbers of macrophages seen in the clinically acute phase (within 2 weeks of relapse onset). Actively demyelinating lesions are diffusely infiltrated by macrophages containing myelin debris stained by KB staining. Chronic active lesions are hypocellular at the lesion centre and hypercellular at the lesion rim (the main component of the cellularity is macrophage/microglia). Chronic inactive lesions are hypocellular throughout the entire lesions.
According to this staging protocol, NMO lesions (n = 67, 59 spinal cord lesions and 8 medullary lesions) were classified into 22 acute inflammatory lesions, 25 actively demyelinating lesions, 8 chronic active lesions and 12 chronic inactive lesions. MS lesions (n = 10) were classified into one actively demyelinating lesion, five chronic active lesions and four chronic inactive lesions.
In each lesion, we judged the immunoreactivity of AQP4, GFAP and MBP as completely lost (lost) or partially preserved (preserved), and divided the main expression patterns of the three molecules in each lesion into the following six patterns: Pattern A (AQP4-lost, GFAP-lost and MBP-preserved), B (AQP4-lost, GFAP-lost and MBP-lost), C (AQP4-lost, GFAP-preserved and MBP-preserved), D (AQP4-lost, GFAP-preserved and MBP-lost), E (AQP4-preserved, GFAP-preserved and MBP-lost) and F (AQP4-preserved, GFAP-preserved and MBP-preserved).
|
Results |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionConclusionsReferences |
|---|
AQP4 and GFAP expression pattern in the spinal cord of normal controls
In the cervical cord of normal control subjects (eight cases), AQP4 was diffusely expressed in the entire cord area, but the staining was stronger in the central grey matter than in the white matter (Fig. 1A). In the grey matter, dense, fine, fibrous structures were stained for AQP4. In the white mater, the fine structures corresponding to radial blood vessels and pia mater were also strongly stained for AQP4 (Fig. 1B) and GFAP (Fig. 1C).
|
Neuropathological and immunohistochemical findings in NMO
General neuropathological findings of NMO lesions
In the spinal cords with NMO lesions, extensive inflammation with oedema, necrosis with cystic changes or cavitation and cord atrophy were commonly seen. With high magnification, inflammatory lesions with or without necrotic changes were often located in the perivascular regions, where there were perivascular cuffing of mononuclear and polymorphonuclear cells (in the clinically acute phase), infiltration of macrophages and microvessel proliferation around small vessels with thickened walls. Thirty-five (59%) out of 59 spinal cord NMO lesions occupied over half the area of the spinal cord sections. In contrast, in MS, the spinal cord lesions were relatively small, and 6 out of 10 cord lesions were mainly localized in the white matter. Peripheral rims of the cord were relatively spared in all NMO cases, while demyelinating plaques in MS involved the periphery of the cord.
In the cerebral and cerebellar hemispheres of NMO, there were absolutely no lesions in four cases and only a few, small, ischaemic or demyelinating white matter lesions except two cases with multiple or diffuse lesions (NMO7 and NMO12). In the medulla oblongata, there were eight NMO cases with acute inflammatory and active demyelinating lesions, with cystic changes as described in the spinal cord lesions of NMO. The optic nerve from a single case of NMO also had a similar acute inflammatory lesion with necrosis and cysts (data not shown).
Immunohistochemical findings of NMO lesions
Immunohistochemical pattern of AQP4, GFAP and MBP in four NMO lesion stages
As summarized in Table 3, the NMO lesions were subdivided into ‘acute inflammatory’ (22 lesions), ‘actively demyelinating’ (25 lesions), ‘chronic active’ (8 lesions) and ‘chronic inactive’ (12 lesions) types.
|
In the acute inflammatory lesions, relatively preserved myelin with complete loss of AQP4 and GFAP (Pattern A) was the main feature (73%), and AQP4 was lost in all lesions (100%). The loss of AQP4 accompanied by the loss of GFAP staining (Patterns A and B) was evident in 86% of the lesions. In actively demyelinating lesions, the expression patterns of GFAP and MBP were varied (Patterns A–D), but AQP4 was lost in all but one lesion (96%). The loss of AQP4 accompanied by the loss of GFAP staining (Patterns A and B) was seen in 56% of the lesions. In chronic active lesions, cystic AQP4-negative lesions (88%) with mild macrophage infiltration were surrounded by astrocytes and many macrophages. In chronic inactive lesions, the lesions were hypocellular and were often severely necrotic, and were cystic with the loss of AQP4 and MBP but showed partially preserved GFAP immunoreactivity (Pattern D) (50%) except some AQP4- and GFAP-faintly positive lesions (Patterns E and F).
Acute inflammatory lesions (Table 3)
In acute inflammatory lesions (Fig. 2), Pattern A was the most common. In these lesions, AQP4 immunoreactivity was completely lost in extensive regions, especially in the lesion cores and in the perivascular areas along the radial blood vessels in the white matter where perivascular depositions of complement C9neo were present (Fig. 2A and D). In some lesions, loss of AQP4 immunoreactivity extended to the cord rim beneath the pia mater. Immunoreactivity for GFAP was also largely lost or decreased (Fig. 2B) in the lesions, and they were often surrounded by areas with stronger GFAP staining (Fig. 2B) than that in control white matter (Fig. 1C). As shown in Fig. 2A, perivascular white matter lesions lacking AQP4 around C9neo-stained vessels, were surrounded by AQP4-rich reactive astrogliosis. The pattern of the perivascular loss of GFAP immunoreactivity surrounded by areas with diffusely increased GFAP immunoreactivity (Fig. 2B) was essentially similar to the findings of AQP4 (Fig. 2A).
|
On the other hand, MBP-stained myelinated fibres were relatively preserved in those lesions (Fig. 2C). These preserved myelinated fibres were not stained with P0 antibody. In a more severely destroyed lesion (Fig. 2E and F) lacking AQP4 and GFAP, P0 stained myelinated fibres were seen in the part of the dorsal portion of the cord as we previously reported (Itoyama et al., 1985
). With high magnification of double staining with MBP and C9neo, MBP immunostaining was remarkably decreased at the lesion core (Fig. 2G), and was also partially decreased at the periphery of the perivascular C9neo-deposited lesion lacking AQP4 and GFAP (Fig. 2H), but myelinated fibres without thinly remyelinating changes or myelin debris were seen at the periphery of C9neo-positive or negative areas (Fig. 2H and I), suggesting myelin preservation. In addition, there was axonal loss evidenced by neurofilament debris in the lesion core (Fig. 2J).
Actively demyelinating lesions and chronic lesions (Table 3)
In actively demyelinating lesions, the expression patterns of AQP4, GFAP and MBP were heterogeneous, including Pattern A, which was commonly seen in acute inflammatory lesions. However, as compared with other lesion stages, demyelinating lesions with numerous myelin–debris–laden macrophages and thinly myelinated fibres (Pattern C) (AQP4-completely lost, GFAP- and MBP-partially preserved) were relatively common in actively demyelinating lesions. Pattern A was also observed in chronic active lesions. Patterns D and E were essentially associated with cystic necrosis. Diffuse cystic lesions with various degrees of macrophage infiltration where myelin was absolutely lacking (Pattern D), were commonly seen in chronic active and chronic inactive lesions as well as in actively demyelinating lesions. Some lesions in the late stage showed partially restored AQP4 immunoreactivity (Pattern E). Lesions with preserved immunoreactivity of AQP4, GFAP and MBP (Pattern F) were seen only in chronic inactive lesions.
Perivascular depositions of complements, immunoglobulins and VEGF in NMO
At the perivascular lesions lacking AQP4 (Fig. 3A), there were fine structures stained for GFAP whose immunoreactivity was weaker than that of perivascular astrocytic foot processes in normal controls (Fig. 1C), around dilated blood vessel walls (Fig. 3B), and this area was surrounded by reactive astrogliosis positive for AQP4 and GFAP.
|
With high magnification (Fig. 3C), those GFAP-weakly positive fine structures, probably corresponding to astrocytic foot processes, appeared partially swollen and were observed as rosette-like formations which were also stained with C9neo (Fig. 3D), IgM (Fig. 3E), IgG (Fig. 3F) or VEGF (Fig. 3G) deposited in the perivascular fine structures. Such perivascular deposits of immunoglobulins and complements were observed to be much milder and were less frequently seen in cases of MS and were never encountered in normal controls. VEGF deposition was detected in active lesions.
Immunohistochemical findings of MS lesions and infarctions (Table 4)
The immunohistochemical features of MS lesions (Fig. 4A–E) were quite different from those of NMO lesions (Fig. 4F–J). The lesions in our cases of MS were chronic active or chronic inactive lesions or active demyelinating lesions, and demyelinating plaques were sharply demarcated as areas with the loss of MBP staining with infiltration of macrophages, especially in the lesion rim, and a small amount of myelin debris, but there was no area where AQP4 (Fig. 4A) and GFAP (Fig. 4B) immunoreactivities were lost, and GFAP was stained diffusely in demyelinated (Fig. 4C) and normal appearing white matter (Fig. 4B). Most lesions were partially remyelinated (Pattern F). These features in MS were distinct from those of the NMO lesions including the chronic active and actively demyelinating lesions (Fig. 4F–H) in that the lesions that included shadow plaques with partially preserved MBP staining were clearly identified by the complete loss of AQP4 and GFAP staining.
|
|
With high magnification, in MS, the pia mater and demyelinating lesions (Fig. 4D) were diffusely stained for GFAP as well as AQP4 (Fig. 4E) with many hypertrophic astrocytes and fibrous structures corresponding to astrocytic foot processes. In contrast, only the edges of well-demarcated lesions in NMO were infiltrated with AQP4- and GFAP-stained hypertrophic astrocytes (Fig. 4I and J).
In acute basal ganglia infarction with only early necrotic signs of eosinophilic appearance and cellular cystic changes (Fig. 5A), AQP4 was stained across the whole area of the lesion (Fig. 5B), especially in the perivascular area (Fig. 5C). In acute to chronic infarct lesions where necrotic changes were observed, AQP4 and GFAP were also positive as reactive astrogliosis (Fig. 5D), except in severe necrotic lesions with lost immunoreactivity of AQP4, GFAP and MBP (Table 4).
|
As described earlier, the complete loss of AQP4 from acute to chronic stages as seen in NMO were not observed in any cases of MS or infarction.
|
Discussion |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionConclusionsReferences |
|---|
We previously reported an immunohistochemical study of a case of NMO, in which the spinal cord lesions extended longitudinally from the cervical to thoracic cord (Misu et al., 2006
). In the spinal cord lesions, AQP4 staining was lost especially in the central grey matter of the spinal cord and was associated with the loss of or low GFAP immunoreactivity, while MBP-stained myelinated fibres were relatively preserved (Misu et al., 2006). In the present study in which we examined 67 lesions from 12 cases of NMO, we confirmed the previous findings and clearly demonstrated unique immunocytochemical features in NMO lesions that were distinct from those in MS lesions. They are as follows: (1) NMO lesions were characterized by the loss of or impaired AQP4 and GFAP immunostaining from the early lesion stage (acute inflammatory lesions), (2) MBP stained myelinated fibres were relatively preserved in NMO lesions in the acute inflammatory and actively demyelinating phase, where immunocytochemical changes of AQP4 and GFAP were observed, (3) In MS lesions, neither AQP4 nor GFAP immunoreactivity was lost but was rather increased as compared with normal control white matters.
In MS, it is well-known that reactive astrocytosis is histologically prominent and its GFAP immunoreactivity is always upregulated in and around demyelinated plaques (Holley et al., 2003; Ayers et al., 2004). Recently, Aoki-Yoshino and her colleagues immunocytochemically studied MS lesions using antibody to AQP4. They demonstrated that AQP4 immunoreactivity was increased in lesions of MS as well as those of viral encephalitis. AQP4-stained astrocytes were widely observed in the centre and the periphery of demyelinated MS plaques (Aoki-Yoshino et al., 2005). Their results of AQP4 immunoreactivity in MS lesions were similar to our findings. Therefore, the immunohistochemical features in NMO lesions, especially the loss of AQP4 staining in the lesion, were quite unique to NMO.
AQP4 is abundant in the central nervous system, particularly in the grey matter of the spinal cord, the periventricular area and periaqueductal areas (Jung et al., 1994; Oshio et al., 2004). Also, this water channel protein is densely localized in the astrocytic foot processes (Vizuete et al., 1999), and underlies the pia mater and the microvessels to form the BBB. Interestingly, the distribution of AQP4-rich areas in the central nervous system, such as the hypothalamus or the grey matter of the spinal cord, is compatible with that of NMO lesions (Misu et al., 2005; Nakashima et al., 2006; Pittock et al., 2006). Moreover, in the present study, in NMO lesions the deposition of humoral factors was predominantly observed in perivascular areas, which are known to be occupied by astrocytic vascular feet and to be rich in AQP4. These findings strongly suggested that AQP4 might be involved in the pathogenesis of NMO.
We herein observed NMO lesions immunohistochemically as areas lacking both AQP4 and GFAP immuno-reactivity. We previously reported cases of Japanese OSMS which had large spinal cord lesions lacking GFAP immunoreactivity, and those lesions were filled with Schwann cells and P0-stained remyelinated fibres (Itoyama et al., 1985). The lack of GFAP staining in those OSMS lesions was evident in the central portion of the spinal cords, which was similar to that found in the present study. Our previous and present findings strongly suggest that the loss of astrocytes or astrocytic impairment is closely related to the lesion formation in NMO.
The pathogenetic mechanisms for the loss or downregulation of AQP4 and GFAP in NMO lesions remain to be elucidated. However, since the perivascular deposition of immunoglobulins and activated complements was found in the NMO lesions lacking AQP4 and GFAP staining, it is suggested that complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity, in which NMO-IgG, anti-AQP4 antibody, may be involved, might cause the degradation or downregulation of the water channel protein and eventually damage the astrocytes. It is unresolved what is the initial event or how serum anti-AQP4 antibody crosses the BBB and gains access to the antigen. However, our recent study on anti-AQP4 antibody in NMO showed that the patients’ sera positively stained the cell surface of HEK 293 cells transfected with human AQP4 in a non-permeating condition (Takahashi et al., 2006), indicating that serum anti-AQP4 antibody in NMO recognizes the extracellular domains of AQP4 protein. Thus, it is likely that anti-AQP4 antibody permeating through the BBB binds to AQP4 expressed on the surface of astrocytes to trigger the above-mentioned cytotoxic mechanisms in the perivascular regions of NMO. The primary breakdown of the BBB may allow the secondary influx of humoral or cellular immune components that attack the central nervous system, which could be the cause of the severe necrotic and cavitary lesions. In NMO lesions accompanied by necrotic and cavitary changes, loss of AQP4 and GFAP immunoreactivity was evident and reactive astrogliosis was poor. It is reported that a dysfunction of astroglial migration and delay of wound healing in astroglial monolayers in vitro occur in AQP4-deficient mice (Verkman et al., 2006). Therefore, it is possible that the anti-AQP4 antibody may induce astroglial cell lysis, or inhibit the migration and activation of astrocytes to repair the lesions.
Another important finding in the present study was the finding that MBP-stained myelinated fibres were relatively preserved in NMO lesions where AQP4 and GFAP immunoreactivities were widely lost. This is in contrast to the findings that immunoreactivity to myelin proteins such as MBP or myelin-associated glycoprotein was lost in plaques of MS (Itoyama et al., 1980). A recent immunopathological study revealed that the perivascular deposition of activated complements and immunoglobulins is a feature of NMO that distinguishes it from MS (Lucchinetti et al., 2002). Anti-AQP4 antibody might also be deposited in the perivascular region causing the loss of AQP4 immunoreactivity as well as the astrocytic impairment in NMO lesions. If anti-AQP4 antibody really plays a crucial role in the pathogenesis of NMO, it would be reasonable that myelins may be preserved or secondarily disturbed after astrocytes are widely destroyed in the process of tissue necrosis. At this point, it remains unknown how the loss of AQP4 might relate to tissue necrosis in NMO, but our data suggest that, unlike MS, inflammatory demyelination is not the primary pathological process in NMO.
|
Conclusions |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionConclusionsReferences |
|---|
In conclusion, the present study provides evidence of a unique pathogenesis in NMO, namely, astrocytic impairment associated with humoral immunity against AQP4 may be primarily involved in NMO lesions. This pathomechanism is quite different from that of MS in which demyelination is the primary pathology. Further analyses using cell cultures and disease animal models are needed to clarify the basic mechanisms targeting AQP4 and astrocytes in NMO.
|
Acknowledgements |
|---|
We wish to thank Dr Fusahiro Ikuta at Brain Research Center, Niigata Neurosurgical Hospital, who kindly gave us much advice, and Dr Kazuhiro Murakami at Tohoku Welfare Pension Hospital, who kindly provided materials for this study. We also wish to thank Mr Brent Bell for reading the manuscript. This work was supported by a grant-in-aid for young researcher (17790569) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Funding to pay the Open Access publication charges for this article was provided by Grant-in-aid of ministry of education, culture, sports, science and technology in Japan.
|
References |
|---|
|
TopSummaryIntroductionMaterial and methodsResultsDiscussionConclusionsReferences |
|---|
Aoki-Yoshino K, Uchihara T, Duyckaerts C, Nakamura A, Hauw JJ, Wakayama Y. Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. Acta Neuropathol (Berl) (2005) 110:281–8.[CrossRef][Medline]
Ayers MM, Hazelwood LJ, Catmull DV, Wang D, McKormack Q, Bernard CC, et al. Early glial responses in murine models of multiple sclerosis. Neurochem Int (2004) 45:409–19.[CrossRef][Web of Science][Medline]
Cloys DE, Netsky MG. Neuromyelitis optica. In: Handbook of clinical neurology.—Viken PJ, Bruyn GW, eds. (1970) 9. Amsterdam: North-Holland. 426–36.
Devic E. Myélite subaiguë compliquée de néurite optique. Bull Med (1894) 8:1033–4.
Gault F. De la neuromyélite optique aiguë [Thesis]. (1894) Lyon.
Holley JE, Gveric D, Newcombe J, Cuzner ML, Gutowski NJ. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol (2003) 29:434–44.[CrossRef][Web of Science][Medline]
Itoyama Y, Sternberger NH, Webster HD, Quarles RH, Cohen SR, Richardson EP. Immunocytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann Neurol (1980) 7:167–77.[CrossRef][Web of Science][Medline]
Itoyama Y, Ohnishi A, Tateishi J, Kuroiwa Y, Webster HD. Spinal cord multiple sclerosis lesions in Japanese patients: Schwann cell remyelination occurs in areas that lack glial fibrillary acidic protein (GFAP). Acta Neuropathol (Berl) (1985) 65:217–23.[CrossRef][Medline]
Jung J, Bhat R, Preston G, Guggino W, Baraban J, Agre P. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA (1994) 91:13052–6.
Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol (2003) 2:117–27.[CrossRef][Web of Science][Medline]
Kuroiwa Y. Neuromyelitis optica (Devic's disease, Devic's syndrome). In: Handbook of clinical neurology.—Koetsier JC, ed. (1985) 47. Demyelinating disease: Elsevier Science Publishers. 397–408.
Lassmann H, Raine CS, Antel J, Prineas JW. Immunopathology of multiple sclerosis: report on an international meeting held at the institute of neurology of the university of Vienna. J Neuroimmunol (1998) 86:213–17.[CrossRef][Web of Science][Medline]
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 202:473–7.
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 364:2106–12.[CrossRef][Web of Science][Medline]
Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 125:1450–61.
Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol (1993) 34:162–8.[CrossRef][Web of Science][Medline]
Misu T, Fujihara K, Nakamura M, Murakami K, Endo M, Konno H, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med (2006) 209:269–75.[CrossRef][Web of Science][Medline]
Misu T, Fujihara K, Nakashima I, Miyazawa I, Okita N, Takase S, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain (2002) 125:2460–8.
Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology (2005) 65:1479–82.
Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry (2006) 77:1073–5.
Oshio K, Binder DK, Yang B, Schecter S, Verkman AS, Manley GT. Expression of aquaporin water channels in mouse spinal cord. Neuroscience (2004) 127:685–93.[CrossRef][Web of Science][Medline]
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 63:390–6.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GF, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 13:227–31.[CrossRef][Web of Science][Medline]
Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med (2006) 210:307–13.[CrossRef][Web of Science][Medline]
Trapp BD, Peterson J, Ransohoff R, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 338:278–85.
Verkman AS, Binder DK, Bloch O, Auguste K, Papadopoulos MC. Three distinct roles of aquaporin-4 in brain function revealed by knockout mice. Biochim Biophys Acta (2006) 1758:1085–93.[Medline]
Vizuete ML, Venero JL, Vargas C, Ilundain AA, Echevarria M, Machado A, et al. Differential upregulation of aquaporin-4 mRNA expression in reactive astrocytes after brain injury: potential role in brain edema. Neurobiol Dis (1999) 6:245–58.[CrossRef][Web of Science][Medline]
Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 53:1107–14.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C-P Lo, H-W Kao, S-Y Chen, C-J Hsueh, W-C Lin, W-L Hsu, D-K Wu, and G-C Liu Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1107 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Matsushita, N Isobe, T Matsuoka, N Shi, Y Kawano, X. Wu, T Yoshiura, Y Nakao, T Ishizu, and J. Kira Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese Multiple Sclerosis, July 1, 2009; 15(7): 834 - 847. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Nishiyama, T. Ito, T. Misu, T. Takahashi, A. Kikuchi, N. Suzuki, K. Jin, M. Aoki, K. Fujihara, and Y. Itoyama A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset Neurology, June 2, 2009; 72(22): 1960 - 1961. [Full Text] [PDF]
|
|
|
|
|
|
M Nakamura, T Misu, K Fujihara, I Miyazawa, I Nakashima, T Takahashi, S Watanabe, and Y Itoyama Occurrence of acute large and edematous callosal lesions in neuromyelitis optica Multiple Sclerosis, June 1, 2009; 15(6): 695 - 700. [Abstract] [PDF]
|
|
|
|
|
|
T Misu, R Takano, K Fujihara, T Takahashi, S Sato, and Y Itoyama Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker J. Neurol. Neurosurg. Psychiatry, May 1, 2009; 80(5): 575 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Doi, T Matsushita, N Isobe, T Matsuoka, M Minohara, H Ochi, and J. Kira Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody Multiple Sclerosis, March 1, 2009; 15(3): 304 - 310. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Jarius, F. Aboul-Enein, P. Waters, B. Kuenz, A. Hauser, T. Berger, W. Lang, M. Reindl, A. Vincent, and W. Kristoferitsch Antibody to aquaporin-4 in the long-term course of neuromyelitis optica Brain, November 1, 2008; 131(11): 3072 - 3080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Vincent, P. Saikali, R. Cayrol, A. D. Roth, A. Bar-Or, A. Prat, and J. P. Antel Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment J. Immunol., October 15, 2008; 181(8): 5730 - 5737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Takahashi, I Miyazawa, T Misu, R Takano, I Nakashima, K Fujihara, M Tobita, and Y Itoyama Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1075 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Okamoto, M. Ogawa, Youwei Lin, M. Murata, S. Miyake, and T. Yamamura Review: Treatment of neuromyelitis optica: Current debate Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 43 - 52. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Waters, S. Jarius, E. Littleton, M. I. Leite, S. Jacob, B. Gray, R. Geraldes, T. Vale, A. Jacob, J. Palace, et al. Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis Arch Neurol, July 1, 2008; 65(7): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hudson, C. Mowbray, J. L. Elson, A. Jacob, M. Boggild, A. Torroni, and P. F. Chinnery Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)? Brain, April 1, 2008; 131(4): e93 - e93. [Full Text] [PDF]
|
|
|
|
|
|
A. Compston Complexity and heterogeneity in demyelinating disease Brain, May 1, 2007; 130(5): 1178 - 1180. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||